Crossmark

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib

Published Online: 2014-12-09

Published Print: 2015-05

Authors

Guinn, D

Ruppert, A S

Maddocks, K

Jaglowski, S

Gordon, A

Lin, T S

Larson, R

Marcucci, G

Hertlein, E

Woyach, J

Johnson, A J

Byrd, J C
License Information

Text and Data Mining valid from 2014-12-09

Version of Record valid from 2014-12-09
More Information

Article History

First Online: 9 December 2014

Competing interests

: The authors declare no conflict of interest.

Document is current